Please assess the completion status of the following clinical trial:

Trial Title: Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of recessive dystrophic epidermolysis bullosa (RDEB)~2. 13 years old or older and willing and able to give assent/consent~3. Confirmation of RDEB diagnosis by immunofluorescence (IF) and electron microscopy (EM)~4. NC1\[+\] and mAb LH24 antibody staining negative~5. RDEB type VII collagen mutations in subject and carrier parents confirmed~6. At least 100 to 200 cm2 areas of open erosions on the trunk and/or extremities suitable for skin grafting~7. Able to undergo adequate anesthesia to allow grafting procedures to take place.~Exclusion Criteria:~1. Medical instability limiting ability to travel to Stanford University Medical Center~2. The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as active infection with HIV, hepatitis B or hepatitis C, as determined by hepatitis B surface antigen screening, detection of hepatitis C antibodies, or positive result of hepatitis C polymerase chain reaction (PCR) analysis.~3. Antibodies to type VII collagen associated antigens~4. Active infection in the area that will undergo grafting~5. Evidence of systemic infection~6. Current evidence or a history of squamous cell carcinoma in the area that will undergo grafting~7. Active drug or alcohol addiction~8. Hypersensitivity to vancomycin or amikacin~9. Receipt of chemical or biological study product for the specific treatment of RDEB in the past six months~10. Positive pregnancy test or breast-feeding~11. Clinically significant abnormalities (Grade 2 or higher on the National Cancer Institute \[NCI\] toxicity scale) on laboratory tests performed prior to grafting, except for the following specific exclusionary laboratory threshold results, subject to approval or exemption by the EB physician:~    * Albumin \< 2.5 g/dL~   * Leukocytes \> 20K/uL~   * Hemoglobin \< 7.5 g/dL. Low hemoglobin will be treated at the discretion of the investigators and the EB physician.~   * Additional exceptions may be made at the discretion of the investigators and the EB physician.~12. Clinically significant abnormalities (Grade 2 or higher on the NCI toxicity scale) identified through medical history and physical examination on Day 0, with the following exceptions:~    * Anorexia, can enroll up to Grade 4 (inclusive)~   * Constipation, can enroll up to Grade 2 (inclusive)~   * Dysphagia, can enroll up to Grade 4 (inclusive)~   * Keratitis, can enroll up to Grade 4 (inclusive)~   * Bone pain, can enroll up to Grade 2 (inclusive)~   * Additional exceptions may be made at the discretion of the investigators and the EB physician.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEAES treatment (Type: EXPERIMENTAL): LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete